Back to search

Article

Neuro-Adverse Events Associated with GLP-1 Receptor Agonists: A Study Based on the FAERS Database and External Validation Using NHANES Database

2026-08-06

Abstract excerpt

<h4>Background</h4> Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely prescribed for type 2 diabetes and obesity, yet their neuropsychiatric safety profile remains incompletely characterized. We aimed to systematically evaluate neuro-adverse event (AE) signals for six GLP-1RAs and to validate key findings using population-based data. <h4>Methods</h4> We conducted disproportionality analysis of FAER...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a37a52b0-1bb7-59f6-a388-7fbaad3d75c3
DOI
10.64898/2026.08.04.26359670
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Neuro-Adverse Events Associated with GLP-1 Receptor Agonists: A Study Based on the FAERS Database and External Validation Using NHANES DatabaseDOI 10.64898/2026.08.04.26359670
Neurosensory Risk After Semaglutide or Tirzepatide Is Lower Than Matched Antidiabetic and Bariatric Surgery Cohorts and Tracks Glycemic BurdenSemantic proximity
Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity
Substance-Level Disproportionate Reporting of Impaired Gastric Emptying for Five Glucagon-Like Peptide-1 Receptor Agonists: A Reproducible Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity
Legacy neuropsychiatric benefit after semaglutide is linked to maximum achieved dose and independent of the maximum weight lostSemantic proximity
Adverse event analysis and signal detection of calcitonin gene-related peptide inhibitors using the FDA Adverse Event Reporting System databaseSemantic proximity
Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotypingSemantic proximity
Real-World Effectiveness, Safety, and Use Patterns of GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Nationwide Multicentre Community Pharmacy StudySemantic proximity
Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotypingSemantic proximity
GLP1R gene expression is associated with metabolic and mental health effects in a phenome-wide drug repurposing and safety analysisSemantic proximity
Fall Reporting with GLP-1 Receptor Agonists in Older Adults: A FDA Adverse Event Reporting System (FAERS) Disproportionality AnalysisSemantic proximity
Comparative Efficacy and Safety of GLP-1 Receptor Agonists in Neurological and Nephrological Outcomes of Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisSemantic proximity
Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us.Semantic proximity
Select a neighboring publication to make it the new centre.